Table 2.

Cure rates (CR), extended CRs egg-reduction rates (ERR), extended ERRs and reinfection data for the four different treatments against A. lumbricoides infections. Results of baseline and 3 weeks follow-up have been reported elsewhere [13]

Ascaris lumbricoides
	Weeks post-treatment	Albendazole – ivermectin (n = 100)	Albendazole – mebendazole (n = 101)	Albendazole – oxantel pamoate (n = 100)	Mebendazole (n = 104)
Children positive before treatment (%)		46 (46.0)	36 (35.6)	44 (44.0)	43 (41.3)
No. of children cured (CR, 95 % CI)	3 weeks	45 (97.8, 88.5–99.9)	36 (100, 90.3–100.0)	43 (97.7, 88.0–99.9)	41 (95.4, 84.2–99.4)
No. of children negative (extended CR, 95 % CI)	18 weeks	32 (69.6, 54.2–82.3)	25 (69.4, 51.9–83.7)	27 (61.4, 45.5–75.6)	26 (60.5, 44.4–75.0)
Geometric mean: EPG	Baseline	2,385.8	1,195.3	1,503.4	1,095.2
	3 weeks	0.1	0.0	0.2	0.4
	18 weeks	6.9	9.1	12.5	10.6
ERR (95 % CI)	3 weeks	99.9 (99.9–100.0)	100 (−)	99.9 (99.9–100)	99.9 (99.8–100)
Extended ERR (95 % CI)	18 weeks	99.7 (99.1–99.9)	99.2 (97.5–99.8)a	99.2 (97.1–99.8)a	99.0 (97.7–99.6)a
No. of children positive (prevalence, 95 % CI)	Baseline	46 (46.0, 36.1–55.9)	36 (35.6, 26.1–45.1)	44 (44.0, 34.1–53.9)	43 (41.3, 31.7–51.0)
	3 weeks	1 (1.0, −1.0–3.0)	2 (2.0, −0.8–4.7)	3 (3.0, −0.4–6.4)	2 (2.0, −0.8–4.6)
	18 weeks	24 (24.0, 15.5–32.5)	28 (27.7, 18.8–36.6)	33 (33.0, 23.6–42.4)	33 (31.7, 22.6–40.8)
Reinfections (%, 95 % CI)	18 weeks	14/45 (31.1, 18.2–46.6)	11/36 (30.6, 16.3–48.1)	16/43 (37.2, 23.0–53.3)	16/41 (39.0, 24.2–55.5)
New infections (%, 95 % CI)	18 weeks	10/54 (18.5, 9.3–31.4)	17/63 (27.0, 16.6–39.7)	15/54 (27.8, 16.5–41.6)	16/61 (26.2, 15.8–39.1)

Data are n (%, 95 % CI) unless otherwise indicated. EPG = egg per gram of stool

^aSignificantly lower ERR compared to the 3 weeks ERR (no overlapping confidence interval assumption)